Mastitis (udder inflammation), which is a production limiting disease in cattle and has an estimated £14-23 billion impact on the global dairy industry, is currently detected by visual inspection of milk, temperature monitoring or via time-consuming laboratory methods, all of which have limitations.
The project is worth £805k over a 30 month project period and will be undertaken in partnership with the University of Glasgow (UofG). It aims to combine the diagnostic assay development expertise of Abingdon with the animal health and biomarker knowledge of the UofG in order to develop a highly sensitive and specific assay with the ability to stratify mastitis by bacterial class (gram-negative or gram-positive), thus offering fast, on-farm decision making about antimicrobial treatment of cows with mastitis and providing an opportunity to reduce antimicrobial use whilst safeguarding cow health.
Professor David Eckersall (Professor of Veterinary Biochemistry), UofG’s biomarker expert commented:
The project is the culmination of a decade long research programme where we have identified and characterised, in the laboratory, potential biomarkers for this disease. The project will translate our research into technology that can be used on the farm and also demonstrate its value in the dairy industry.”
UofG’s Project lead Professor Ruth Zadoks (Professor of Molecular Epidemiology) adds:
“The pressure to reduce the use of antimicrobials in food production is growing rapidly and some countries have already imposed limitations on antimicrobial use, such as quota. We must provide dairy farmers with the tools to minimize antimicrobial use without jeopardizing cow health or food safety. This project, and the School of Veterinary Medicine’s good relationship with the dairy industry, enable us to do so.”
Abingdon’s Chief Technology Officer, Dr David Pritchard, commented:
“We are very much looking forward to collaborating with the University of Glasgow to start translating their research into a commercially available product that can not only detect mastitis but also guide treatment. We believe that this test will provide benefits to the dairy industry in terms of milk quality and yield and to the cattle in terms of animal welfare. In addition, there will be public health benefits resulting from reduced antimicrobial use.”
Abingdon is a UK-based developer and manufacturer of lateral flow immunoassay tests and readers.
Internally Abingdon is focused on developing lateral flow assays in partnership with key opinion leaders that meet currently unmet needs. In addition, Abingdon offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon takes projects from initial concept through to routine and large-scale manufacturing. Abingdon’s patented lateral flow reader, the ADxLR5®, is CE marked and FDA registered and can be fully customised to meet the needs of clients looking for a quantitative solution for a lateral flow assay.
Ranked in the top 100 of the world’s universities, the University of Glasgow deliver world-class and world-changing research and education with impact. The University of Glasgow (UoG) is a member of the prestigious Russell Group of leading UK Universities and is joint 1st in this group for student satisfaction. UoG is connected to seven Nobel Laureates, and 81% of its research is judged to be internationally excellent. Further information can be found here: http://www.gla.ac.uk/explore/
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information, visit www.innovateuk.gov.uk.